GlaxoSmithKline plc (NYSE:GSK) Stake Lowered by Baldwin Investment Management LLC

Saturday, 23 October 2021, 13:58:46
Baldwin Investment Management LLC reduced its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 9.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,408 shares of the pharmaceutical companys stock after selling 592 shares during the period. Baldwin Investment Management []
— Transcript Daily

Travel Vaccines Market Is Booming Worldwide with Pfizer, Sanofi, GlaxoSmithKline, Merck

Saturday, 23 October 2021, 07:07:20
Advance Market Analytics published a new research publication on Travel Vaccines Market Insights, to 2026 with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities
— OpenPR

Silvercrest Asset Management Group LLC Sells 3,900 Shares of GlaxoSmithKline plc (NYSE:GSK)

Friday, 22 October 2021, 17:34:49
Silvercrest Asset Management Group LLC lowered its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 0.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 465,062 shares of the pharmaceutical companys stock after selling 3,900 shares during the quarter. Silvercrest Asset Management Group LLCs holdings []
— Transcript Daily

Nasal Drug Delivery Systems Market 2028 Rising Demand and International Forecast Scope Led by Top Key Players Merck & Co., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson

Friday, 22 October 2021, 10:56:48
Nasal Drug Delivery Systems Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading
— OpenPR

GlaxoSmithKline (LON:GSK) Given New GBX 1,540 Price Target at Berenberg Bank

Friday, 22 October 2021, 08:26:41
GlaxoSmithKline (LON:GSK) had its price target decreased by Berenberg Bank from GBX 1,625 ($21.23) to GBX 1,540 ($20.12) in a report issued on Monday, Analyst Ratings Network reports. Berenberg Bank currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on GSK. Morgan Stanley decreased their target []
— Dakota Financial News